inc hold pt triple-beat solid comp guidanc believ
upsid alreadi reflect share price rais pt analyst stephen anderson full summari
tableau softwar inc data hold multipl metric point high-teen ep growth vs guidanc remov price
iec electron corp iec buy pt average book past quarter power share gain
 rais pt reiter buy rate analyst nehal chokshi full summari
inc buy pt increas estim water infrastructur continu adopt new technolog
base review yesterday result analyst tate sullivan cfa full summari
bionano genom inc bngo buy pt awar build adopt public saphyr use genet diseas
capricor inc capr hold dose dmd studi analyst jason mccarthi ph full
corpor event call maxim salesperson inform
charl colvard ltd cthr ndr new york ceo/presid suzann miglucci cfo clint pete tue feb
custom inc cover diana ndr connecticut ceo jay sidhu tue march
onconova ontx cover mccarthi kol breakfast event nyc dr lewi silverman dr
rajwanth veluswami thu feb et
athersi inc cover mccarthi ndr nyc ceo gil van bokkelen thu feb
sintx technolog inc sint ndr new york ceo sonni bal vice-president oper david brian mon-tu
oncosec medic inc onc cover mccarthi ndr nyc ceo daniel oconnor cfo sara bronstein
brainstorm cell bcli cover palomequ ndr nyc ceo chief execut offic
ralph kern cfo eyal rubin wed-thu feb
bioporto a/ biopor ndr new york ceo peter morch cfo ole larson fri feb
biotim inc cover mccarthi ndr nyc ceo brian culley cfo brandi robert tue feb
intec pharma ntec cover mccarthi kol dinner nyc ceo jeffrey meckler dr karl kierbutz dr
chesapeak util corpor cover sullivan ndr milwauke cfo beth cooper treasur
chesapeak util corpor cover sullivan ndr chicago cfo beth cooper treasur
global inc cover sullivan ndr nyc ceo dickerson wright fri feb
cover sullivan ndr boston ceo denni sadlowski cfo matthew
genco ship trade ltd cover jang ndr chicago ceo john wobensmith cfo
navig hold ltd nvg cover jang group luncheon new york ceo david butter thu
pm
cover jang ndr boston ceo gari vogel cfo frank decostanzo
director strategi busi develop costa tsoutsoplid tue apr
inc cover confer call cfo tonya robinson director
financi analysi michael bailen mon pm et
univers mcloud corpor mcld cover chokshi ndr new york ceo russ mcmeekin mon-w
univers mcloud corpor mcld cover chokshi ndr greater miami ceo russ mcmeekin wed
corpor ctrl cover chokshi ndr chicago cfo mark novakovich mon feb
corpor ctrl cover chokshi ndr boston cfo mark novakovich tue feb
sifi technolog limit sifi cover klee ndr nyc svp financ gangadharan venugop wed
agilysi inc cover klee ndr chicago cfo toni pritchett vice-president financ dave wood thu
cover klee ndr chicago presid ceo michael prior cfo justin
cover klee ndr milwauke presid ceo michael prior cfo
inc cover klee ndr nyc ceo steve picket cfo ahlstrom tue apr
inc cover klee ndr boston ceo steve picket cfo ahlstrom wed apr
inc cover klee ndr milwauke ceo steve picket cfo ahlstrom thu apr
triple-beat solid comp guidanc
believ upsid alreadi reflect share price rais
pt
maintain hold rate chipotl mexican grill though rais
price target follow triple-beat decemb
pro forma ep pro forma estim
well-abov consensu
compani beat comp read vs maxim
street well restaurant-level ebitda margin read vs
maxim street
importantli transact growth turn posit expect similar
sale traffic trend continu credit growth digit
sale y/i well strength off-premis sale
initi comp guidanc mid-single-digit growth vs pre-releas estim
maxim street revis estim
rais pro forma ep estim
pro forma ep estim ep estim
expect margin expans continu share
buyback resum
howev light gain sinc late decemb low
recommend chase share higher
ep pro forma actual vs maxim may compar
street mean ep inclus charg
revenu actual vs maxim street
comp actual vs maxim street
restaurant-level ebitda margin actual vs maxim
street
ep manag typic provid ep guidanc vs pre-releas
estim maxim street revis estim
comp initi guidanc mid-single-digit comp growth vs pre-releas estim
maxim street revis estim
new unit open manag still expect open unit vs
maxim street estim unit unchang
light gain sinc late decemb low believ
potenti upsid on-going initi balanc potenti
risk base yesterday close price share trade revis
ep estim even increas valuat multipl target
slightli reflect transact growth margin gain even higher labor cost
still believ cmg posit price market base revis
ep estim new forward price-to-earnings multipl target vs prior
ep estim forward price-to-earnings multipl target arriv new
price target price target also correspond forward ev/ebitda
ratio use base valuat year cmg five-year pre-
crisi averag ratio
click full note
average book past quarter
power share gain rais pt reiter buy
strong bottom-lin perform cash oper temporarili
pressur passiv compon shortag
decemb quarter book impress bring past
quarterli book averag estim y/i power
market share gain
rais estim price target reiter
strong bottom-lin perform cash oper temporarili
pressur passiv compon shortag iec report decemb quarter
revenu y/i q/q estim gross profit
margin gm bp q/q bp y/i bp estim
ep well estim strong bottom line beat
larg result strong gm result manag comment due
better effici util overhead rather product mix vertic
perspect vertic modestli q/q aerospac defens q/q
y/i medic q/q y/i industri q/q y/
oper vs estim delta
due day higher cash convers cycl model model
day result continu stockpil raw materi q/q take
account on-going compon shortag manag note stockpil
non-depreci compon multi-lay ceram capacitor
believ compon whose cost basi tie moor law cpu
dram nand flash etc typic passiv compon manag note
supplier indic expect lead time start shorten
enabl iec bring inventori level thu cash
convers cycl back level earli part sept end
decemb quarter book impress bring past
quarterli book averag estim y/i power
market share gain iec report book bill ratio impli
book y/i tough comp y/i see
figur book bring past quarter averag book
estim y/i increas note past quarter
revenu averag growth y/i quarter lap y/i declin
recent quarterli y/i growth lap y/i increas per figur
show revenu significantli outperform primari peer em
divis spa md divis growth basi well
basi take account uniqu situat customer-
driven slowdown revenu recogn base analysi shown figur
strongli believ iec gain market share consist manag
commentari market share gain driven improv respons
custom order result jeff schlarbaum return iec ceo februari
two year left presid also brought better balanc
rais estim price target reiter buy
rate given strong book decemb quarter strong bottom-
line decemb quarter result analysi iec systemat take market
share within specialti electron manufactur servic space see figur
comfort rais revenu estim backlog
current oper profit y/i
correspond ebit margin compar long-term ebit margin
estim ep estim effect unchang result
iec recogn non-cash defer tax expens continu
recogn go forward expect nol consum end
basi alreadi account tax rate rais
ep rais effect correspond rais
price target base multipl ep
estim discount back year discount rate
click full note
multipl metric point high-teen ep growth vs
decemb quarter result basi consensu though
dec y/i spend multipl metric point high-teen ep growth vs
guidanc
reiter hold rate introduc estim basi
remov price target histori project
decemb quarter result basi consensu though
deceler still appar basi data report decemb quarter
revenu y/i high-end guidanc rang
licens revenu exceed consensu estim
show deceler y/i growth y/i sept y/i
dec mainten servic slightli miss consensu estim
also show deceler y/i revenu growth sept
dec subscript y/i exceed estim
though miss consensu estim impli new subscript
impress beat estim time appear
miss consensu estim opex slightli
consensu estim result loss per share
correspond consensu estim
believ merit manag content licens book
ratabl vs make tougher y/i growth
guidanc impli y/i revenu growth rel guidanc impli
y/i revenu growth howev also note dec spend
basi deceler y/i growth compar
start y/i growth march
manag contend overal y/i guid y/i
midpoint best metric gaug busi health note
artifici tailwind convert effect mainten per seat
subscript per seat given qualit data point suspect
true health busi trend high-teen deceler
pace dec given data point analysi believ data
set high-teen growth rather guid y/i growth go forward
reiter hold rate introduc estim basi remov
price target histori project basi
introduc estim show rais prior forward
estim basi project revenu
y/i ep y/i revenu estim
y/i ep y/i reiter hold rate
remain concern lurk threat msft power bi well increment
concern regard prior assumpt data fall short compound-annual-growth-rate
target remov price target get confid around
consist model given adopt render increas defer
revenu de minimu driver non-gaap net incom predominantli
subscription-bas model howev note manag guid long-term
assumpt compani gener ebit margin
continu grow compound-annual-growth-rate ebit guidanc revenu
click full note
increas estim water infrastructur continu
adopt new technolog base review yesterday
review yesterday quarterli result increas ep
ep street-high price target
maintain buy rate share base custom continu
adopt new water meter technolog competit advantag
water meter market includ long-term custom relationship
focu meter competitor stabl oligopoli market
yesterday report oper ep recently-
lower estim consensu
previous lower ep account
risk potenti order delay sequenti declin oil middl east
result manag comment favor sale mix
togeth indic custom continu buy water meter without
move part transmit read cellular network
revenu oper incom margin increas
prior year base improv sale mix report revenu increas
y/i last year y/i growth also oper incom margin exclud
retir charg increas prior year believ
quarterli result indic higher-margin ultrason meter increas
percent revenu prior year also calcul gener million
free cash flow compani use reduc debt million
expect complet acquisit integr water qualiti
measur equip manag indic investor present
compani use greater free cash flow acquisit
histor may also consid buy flow measur compani
countri base present
rais price target current trade
ep estim new price target base unchang
ep estim prior appli premium multipl roper
technolog rate pe multipl rate
multipl base concentr exposur water meter market
sell type equip servic addit continu
forecast increas dividend second half
increas
recommend buy share base custom adopt new water
meter technolog expect old water meter industri continu adopt
new technolog order measur water flow effici real time
gener water meter busi help manag declin amount clean water
grow popul success transform bring new technolog
old industri lead new peak ep support premium multipl
share
click full note
awar build adopt public saphyr use
bionano announc releas public china-bas
use saphyr analyz sampl obtain molecular diagnos
fshd form adult muscular dystrophi diseas driven
structur variat sv make ideal instrument saphyr
sv map genet sequenc
public research compar saphyr common method
southern fish diagnos fshd found saphyr advantag
reduc workflow blot fish labor intens slow
saphyr simpler sampl prep mostli autom much
easili interpret result vs southern fish anoth advantag
saphyr easili interpret optic map analyz bionano
proprietari softwar reduc genom nois align
optic map structur variat sv identif
moder sampl requir moder sampl requir
saphyr combin rel short time-fram result may
make possibl option prenat applic
conclus gener sv map saphyr genom
cytogenet view bridg gap avail method interrog
genom short long read sequenc short read
 nr longer read pacbio nr acquir
limit sv detect abil major driver diseas includ
cancer build awar via public key bionano
help drive increas saphyr adopt time
valid public fshd link fshd autosom domin adult
muscular dystrophi affect individu diseas associ
chromosom region consist multipl copi repeat
call healthi individu upward copi allel affect
individu tend fewer allel length repeat make tradit
method difficult compound presenc similar repeat
chromosom paper titl clinic applic singlemolecul optic
map multigener pedigre publish molecular genet
genom medicin demonstr diagnost util saphyr fshd
studi includ sampl pedigre test
diagnost util saphyr optic map compar southern blot fish-
base molecular comb saphyr abl accur diagnos diseas
normal haplotyp well founder diseas allel
repeat addit one branch pedigre saphyr detect rare disease-
caus duplic event seem result milder form fshd
research found saphyr produc simplifi workflow use
nick enzym allow accur map isol target
region could carri oper molecular lab rather
requir specialist laboratori addit moder sampl requir
short analysi time-frame could make saphyr use tool prenat applic
particularli urgent request
click full note
dose dmd studi
capricor announc resum dose trial
test alreadi enrol patient duchenn muscular
recal voluntari hold origin place trial decemb
patient sever allerg reaction form anaphylaxi howev
due posit feedback fda hold lift initi
pre-med strategi prevent treat allerg reaction
though dose resum capricor enrol addit patient
addit fund secur patient enrol far target
compani also reduc staff full-tim employe
reduc expens better align resourc personnel compani
conclus resumpt dose posit effort conserv
capit howev compani still face capit constraint need
financ and/or explor strateg altern may bring non-dilut
capit continu enrol patient dmd studi maintain hold
hope-duschenn trial publish capr also previous announc public
phase hope-duschenn data medic journal neurolog link
studi publish januari highlight signific improv
cardiac skelet music function patient advanc stage dmd
prior hope-duschenn trial hope-duschenn trial phase
random control open-label trial evalu safeti efficaci
intracoronari allogen cardiosphere-deriv cell patient dmd
trial conduct period consist patient
year old substanti myocardi fibrosi random took
place patient receiv either standard care control intracoronari
infus cell cardiac skelet muscl function assess mri
perform upper limb pul respect compar baselin mri
month reveal signific scar size reduct improv inferior wall
systol thicken control patient mid-dist pul improv
month lower function patient control
addit seriou safeti issu found contribut treatment
safeti support clinic research
current trial trial random double-blind placebo-
control phase trial focu non-ambulatori patient dmd trial
design base prior hope-duchenn studi follow meet
fda may potenti reduc size patient
trial current patient enrol includ young men boy
advanc stage dmd patient receiv cell vs cell four
iv infus vs intracoronari year evalu use upper arm pul
improv primari endpoint endpoint clinic meaning dmd
patient wheelchair-bound need upper arm muscl mobil eat take
care eleven expect site open trial
could potenti accept registr given unmet need dmd
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
